36 Participants NeededMy employer runs this trial

Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder

(GPAT Trial)

LM
VC
Overseen ByVictoria Culkin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity.

Are You a Good Fit for This Trial?

Inclusion Criteria

I am between 18 and 89 years old.
I am willing and able to stop medications that could affect psilocybin if needed.
* Ability to read, speak, and understand English
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive group-format psilocybin-assisted therapy

12 weeks
Multiple sessions (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 weeks
Follow-up assessments

What Are the Treatments Tested in This Trial?

Interventions

  • Psilocybin

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: GPAT-PTSDExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of New Mexico

Lead Sponsor

Trials
393
Recruited
3,526,000+